Study Tests Potential Herpes Vaccine
A study underway at the University of Alabama at Birmingham (UAB) aims to determine whether an experimental vaccine is safe and effective in preventing genital herpes in young women.
The study marks the final phase of testing for the candidate vaccine, called HERPEVAC, developed by GlaxoSmithKline (GSK).
"If proven effective it will be the first vaccine for a sexually transmitted disease," says Edward Hook, MD, professor of medicine.
Nationally, 40 sites are participating in the study, directed by the National Institute of Allergy and Infectious Diseases and GSK. In total, sites will enroll 7,500 women between the ages of 18 and 30 who do not have oral or genital herpes. UAB will enroll 500 volunteers.
Source: UAB
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
